TD Cowen Maintains Buy on Ultragenyx Pharmaceutical, Lowers Price Target to $18

Benzinga Newsdesk www.benzinga.com Negative 48.2%

Neg 48.2% Neu 0% Pos 0%

TD Cowen analyst Yaron Werber maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Buy and lowers the price target from $49 to $18.